Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 2/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | MLNR | O43193 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976656 | 0.96 | ALDH1A1 (0.46) | SPPL2AALDH1A1LMNAGAAMAPT | |
| SCHEMBL4971626 | 0.95 | SPPL2A (0.40) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| SCHEMBL5024905 | 0.94 | MEP1B (0.42) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| Hydrochloric Acid SCHEMBL4976125 | 0.93 | MEP1B (0.41) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| SCHEMBL4973643 | 0.93 | SPPL2A (0.43) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| SCHEMBL4972913 | 0.92 | ALDH1A1 (0.43) | SPPL2AALDH1A1LMNAGAAMAPT | |
| SCHEMBL5027211 | 0.91 | SPPL2A (0.39) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| SCHEMBL4975302 | 0.91 | SPPL2A (0.41) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| SCHEMBL4974836 | 0.90 | SPPL2A (0.44) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| SCHEMBL4972775 | 0.90 | SPPL2A (0.41) | SPPL2AALDH1A1LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030204097-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-10-30 | — | — | US | claimed |
| US-6316496-B1 | FOR THERAPY OF RETROVIRAL INFECTION; PROPHYLAXIS OF REPLICATION OF RETROVIRUS, THERAPY OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | G. D. SEARLE & CO. | 2001-11-13 | — | — | US | claimed |
| EP-1076062-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2001-02-14 | — | — | EP | claimed |
| US-20080118969-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-05-22 | — | — | US | disclosed |
| US-7161033-B2 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050227926-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-10-13 | — | — | US | disclosed |
| US-6861539-B1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6683210-B2 | HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS, HUMAN IMMUNODEFICIENCY VIRUS, AND LYMPHADENOPATHY ASSOCIATED VIRUS TREATMENT | G. D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-20030204097-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-10-30 | — | — | US | disclosed |
| US-6388132-B1 | AIDS THERAPY | G. D. SEARLE & CO. | 2002-05-14 | — | — | US | disclosed |
| EP-1188766-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. Searle & Co. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6316496-B1 | FOR THERAPY OF RETROVIRAL INFECTION; PROPHYLAXIS OF REPLICATION OF RETROVIRUS, THERAPY OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | G. D. SEARLE & CO. | 2001-11-13 | — | — | US | disclosed |
| EP-1076062-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2001-02-14 | — | — | EP | disclosed |
| US-6150556-A | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) PROTEASE; PROPHYLAXIS AND THERAPY OF RETROVIRUS INFECTIONS | G. D. DEARLE & CO. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6143788-A | ENZYME INHIBITORS | G.D. SEARLE & CO. (US) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227926-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | SPPL2A 654/4885MEP1B 304/4885ALDH1A1 3909/4885 |
| US-20030204097-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | SPPL2A 654/4885MEP1B 304/4885ALDH1A1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.